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and eGFR between 30 and 75 ml/min/1.73 m2, were enrolled in 2
parallel, multinational, double-blind, randomized, placebo-controlled
studies. Subjects were randomized to atrasentan 0.75, 1.25 mg QD or
placebo for 12 wks after a run-in period that maximized the RASi dose.
Results: Mean UACR values (placebo, 0.75, 1.25 mg) at baseline: 671,
878, and 826 mg/g; wk 2: 696 (NS), 573 and 515 mg/g, (p b 0.001);
and wk 12: 797 (NS), 521 and 470 mg/g (p b 0.001). More than 30%
albuminuria reductionwas observed in 51 and 55% of subjects receiving
atrasentan. eGFR (49 ± 13, 48 ± 15, and 51 ± 14ml/min at baseline)
did not change signiﬁcantly compared with placebo. Mean LDL-C
changed by +2± 3,−13 ± 2 and−13 ± 2mg/dl (p b 0.001). Similar
changes were observed in triglyceride levels. No differenceswere noted
in the rate of peripheral edema or heart failure. At week 2, body weight
increased (0.7 and 1.2 kg), but weight was not signiﬁcantly different
from baseline at week 12 for the 0.75 mg group. After stopping
atrasentan for 30 days, all of the parameters described above returned
to pretreatment values. Conclusions: Chronic administration of atra-
sentan reduces albuminuria in patients who are receiving maximum
RAS inhibition without incurring volume-related adverse events.
doi:10.1016/j.lfs.2013.12.226
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Rationale: Idiopathic pulmonary ﬁbrosis (IPF) is characterized by
the formation and proliferation of ﬁbroblast foci. Endothelin-1 induces
lung ﬁbroblast proliferation and contractile activity via the endothelin A
(ETA) receptor. Data from preclinical models suggests that endothelin
blockade can attenuate pulmonary ﬁbrosis. This study tested the
hypothesis that ambrisentan, an endothelin type A receptor speciﬁc
antagonist approved for the treatment of pulmonary arterial hyperten-
sion, reduces disease progression in subjectswith idiopathic pulmonary
ﬁbrosis (IPF). Methods: This was a randomized (2:1), double-blind,
placebo-controlled, event-driven trial enrolling subjects with IPF.
Randomization was stratiﬁed by the presence of pulmonary hyperten-
sion at baseline, determined by a right heart catheterization, and IPF
diagnosis by surgical lung biopsy. The primary endpointwas time to IPF
disease progression, deﬁned as all-cause mortality, adjudicated respi-
ratory hospitalization, or a categorical decrease in lung function deﬁned
as a 10% decrease in forced vital capacity [FVC]with a 5% decrease in the
diffusion capacity for carbon monoxide [DLCO] or a 15 % decrease in
DLCO with a 5% decrease in FVC. Results: At 75% (492 subjects) of the
intended total enrolment and after a mean exposure of 34 weeks to the
study drug, the Data Safety Monitoring Board terminated the study due
to a low likelihood of demonstrating efﬁcacy. From 136 clinical sites,
329 and 163 subjects were randomized to receive ambrisentan or
placebo respectively. At baseline, 36 (11%) and 18 (11%) subjects had
pulmonary hypertension (PH) with a mPAP N 25mmHg and wedge
pressure b 15 mmHg in the ambrisentan and placebo groups respec-
tively. Ambrisentan treated subjects hadmore primary endpoint events
(90 [27.4%] versus 28 [17.2%]), and a 1.74 fold increase in risk of
meeting the primary endpoint (95% conﬁdence interval [CI] 1.14–2.66,
p = 0.010). Evaluation of the primary endpoint components indicated
that the number of deaths (hazard ratio [HR] 2.08, 95% CI 0.75–5.76,
p = 0.100) and subjects with a categorical decrease in lung function
(HR 1.53, 95% CI 0.84–2.78, p = 0.109)was not statistically signiﬁcantly
different between the groups. However, ambrisentan treated subjects
had more respiratory hospitalizations (44 [13%] versus 9 [6%]), and a
2.59 fold increase in risk of experiencing a respiratory hospitalization
(95% CI 1.14–5.89, p = 0.007). Stepwise Cox multivariate analysis
revealed that after adjustment for baseline IPF severity, the risk for
primary events was reduced and the p-value was N0.1 (HR 1.42, 95% CI
0.85–2.05, p = 0.108). Although the risk for respiratory hospitalization
was also reduced, the p-value remained b0.05 (HR 2.11, 95% CI 1.03–
4.33, p = 0.042). The presence of PH at baseline did not affect these
point estimates signiﬁcantly. The secondary endpoints (FVC, DLCO,
6MWD, TDI and QoL) at 48 weeks and the incidence of liver toxicity
were not statistically signiﬁcantly different between the groups.
Conclusions: Ambrisentan was ineffective in reducing disease progres-
sion in IPF and was associated with an increased risk of respiratory
hospitalizations. While there is no evidence of treatment beneﬁt,
all analyses need to be interpreted cautiously as ARTEMIS-IPF was
terminated early for lack of efﬁcacy.
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Background: Endothelin (ET) is a pro-ﬁbrotic vasoconstrictor and a
mediator of microvascular dysfunction and cardiac remodeling. Animal
studies investigating ET receptor blockade in acutemyocardial infarction
led to conﬂicting results regarding ventricular remodeling. In-vitro, ET-A
receptor blockade decreases neutrophil activation. Methods: Patients
with posterior-wall STE-ACS were treated with BQ-123, a selective
ET-A receptor antagonist as previously described (n= 54). Peripheral
blood samples were drawn at baseline, 24 h and 30 days after PCI.
Myeloperoxidase (MPO), matrix metalloproteinase 9 (MMP-9) and the
procollagen III N-terminal propeptide (PIIINP),weremeasured in plasma
using commercially available assays. Results: Patients randomized to
BQ-123 demonstrated a greater reduction ofMPO levels frombaseline to
24 h compared to placebo-treated patients ((177 ng/mL reduction for
BQ-123 versus 108 ng/mL for placebo, p = 0.006), Fig. 1a). In addition,
we observed a signiﬁcantly greater reduction ofMMP-9 levels in patients
treated with study drug (568 ng/mL versus 117 ng/mL, p = 0.018,
Fig. 1b).There was no signiﬁcant difference in PIIINP values. Conclusion:
Short-term administration of BQ-123 reduces MPO and MMP-9 plasma
levels in patients with STE-ACS. In trials with larger patient numbers this
may translate into improved ventricular remodeling at six months.
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